Johnson & Johnson Total Assets 2006-2019 | JNJ
Johnson & Johnson total assets from 2006 to 2019. Total assets can be defined as the sum of all assets on a company's balance sheet.
- Johnson & Johnson total assets for the quarter ending September 30, 2019 were $155.521B, a 0.12% decline year-over-year.
- Johnson & Johnson total assets for 2018 were $152.954B, a 2.76% decline from 2017.
- Johnson & Johnson total assets for 2017 were $157.303B, a 11.4% increase from 2016.
- Johnson & Johnson total assets for 2016 were $141.208B, a 5.84% increase from 2015.
Johnson & Johnson Annual Total Assets
(Millions of US $) |
| 2018 |
$152,954 |
| 2017 |
$157,303 |
| 2016 |
$141,208 |
| 2015 |
$133,411 |
| 2014 |
$130,358 |
| 2013 |
$132,683 |
| 2012 |
$121,347 |
| 2011 |
$113,644 |
| 2010 |
$102,908 |
| 2009 |
$94,682 |
| 2008 |
$84,912 |
| 2007 |
$80,954 |
| 2006 |
$70,556 |
| 2005 |
$58,864 |
Johnson & Johnson Quarterly Total Assets
(Millions of US $) |
| Q3 2019 |
$155,521 |
| Q2 2019 |
$155,117 |
| Q1 2019 |
$150,027 |
| Q4 2018 |
$152,954 |
| Q3 2018 |
$155,703 |
| Q2 2018 |
$155,365 |
| Q1 2018 |
$156,625 |
| Q4 2017 |
$157,303 |
| Q3 2017 |
$155,658 |
| Q2 2017 |
$152,807 |
| Q1 2017 |
$144,918 |
| Q4 2016 |
$141,208 |
| Q3 2016 |
$140,369 |
| Q2 2016 |
$139,814 |
| Q1 2016 |
$136,231 |
| Q4 2015 |
$133,411 |
| Q3 2015 |
$133,266 |
| Q2 2015 |
$132,036 |
| Q1 2015 |
$128,590 |
| Q4 2014 |
$130,358 |
| Q3 2014 |
$132,097 |
| Q2 2014 |
$135,200 |
| Q1 2014 |
$133,330 |
| Q4 2013 |
$132,683 |
| Q3 2013 |
$126,933 |
| Q2 2013 |
$124,325 |
| Q1 2013 |
$121,536 |
| Q4 2012 |
$121,347 |
| Q3 2012 |
$118,951 |
| Q2 2012 |
$115,750 |
| Q1 2012 |
$116,194 |
| Q4 2011 |
$113,644 |
| Q3 2011 |
$111,821 |
| Q2 2011 |
$112,114 |
| Q1 2011 |
$108,150 |
| Q4 2010 |
$102,908 |
| Q3 2010 |
$98,247 |
| Q2 2010 |
$92,300 |
| Q1 2010 |
$93,441 |
| Q4 2009 |
$94,682 |
| Q3 2009 |
$91,558 |
| Q2 2009 |
$87,438 |
| Q1 2009 |
$86,100 |
| Q4 2008 |
$84,912 |
| Q3 2008 |
$87,724 |
| Q2 2008 |
$88,113 |
| Q1 2008 |
$85,995 |
| Q4 2007 |
$80,954 |
| Q3 2007 |
$78,665 |
| Q2 2007 |
$74,683 |
| Q1 2007 |
$73,066 |
| Q4 2006 |
$70,556 |
| Q3 2006 |
$61,238 |
| Q2 2006 |
$60,990 |
| Q1 2006 |
$62,133 |
| Q4 2005 |
$58,864 |
| Q3 2005 |
$56,574 |
| Q2 2005 |
$54,553 |
| Q1 2005 |
$54,446 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$345.696B |
$81.581B |
|
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
|
